Ipilimumab plus nivolumab improved PFS over nivolumab alone in MSI-H/dMMR mCRC, with no new safety concerns. The combination showed higher overall response rates and a favorable safety profile ...

Final results from the pivotal CheckMate 238 trial showed adjuvant nivolumab continues to significantly improve RFS compared with ipilimumab for patients with advanced melanoma, according to data ...

Nivolumab shows lasting melanoma recurrence prevention, with long-term safety, in largest-ever CheckMate 238 trial analysis.

The median duration of recurrence-free survival was 61.1 and 24.2 months with nivolumab and ipilimumab, respectively, at a minimum follow-up of 107 months.

Sweis, MD, and participants discussed their impressions of combination trials in non–clear cell renal cell carcinoma. Non-clear cell renal cell carcinoma (nccRCC) is a less common disease state than ...

The winner of a 2025 SITC grant examines mechanisms that may help explain why drugs that work for some forms of lymphoma ...

Two therapies can be better than one for treating some cancers, concludes a Yale study published Oct. 22 in JCI Insight that ...

The efficacy of nivolumab plus ipilimumab compared with chemotherapy alone was evaluated through a meta-analysis, 1 using HRs to determine the efficacy. A random-effects model was utilized to pool all ...

Over the past decade, subcutaneous formulations of anticancer drugs—originally administered intravenously—have been ...

New research shows COVID-19 mRNA vaccines could make cancer immunotherapy more effective, improving survival for patients ...

Today, the Innovative Cancer Medicines (ICM) initiative announced the enrollment of the first Nigerian patient in a pioneering demonstration project to provide an immunotherapy drug used to treat ...

Investigators conducted a network meta-analysis of phase 3 trials on MIBC treatments to provide comparative ranking of perioperative therapies.